ArriVent BioPharma (AVBP) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed ArriVent BioPharma (AVBP) over the past year, losing 1.5% versus a loss of 20.8%. ArriVent BioPharma is the larger company by market cap ($824.9 million vs $746.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | GYRE |
|---|---|---|
| Share price | $16.73 | $7.04 |
| Market cap | $824.92M | $746.48M |
| 1-day change | +0.12% | +4.14% |
| YTD return | -16.85% | -0.28% |
| 1-year return | -20.82% | -1.54% |
| 5-year return | — | -88.27% |
| Forward P/E | — | 117.33 |
| EPS (TTM) | $-3.62 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $9.42 |
| 52-week low | $11.36 | $5.44 |
| Distance from 52-week high | -53.31% | -25.27% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +82.31% | +165.20% |
| Average volume | 928.78K | 106.08K |
| Shares outstanding | 49.31M | 106.03M |
| Employees | 77 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed AVBP by 19.3 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
AVBP vs GYRE FAQ
Which is bigger, ArriVent BioPharma or Gyre Therapeutics?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $824.92M compared with $746.48M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, AVBP or GYRE?
GYRE returned -1.54% over the past 12 months, compared with -20.82% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.